● CURRENT POSITION
October 2022-today. Senior Assistant Professor of Physiology, Department for Life Quality Studies, University of Bologna, Italy.
● QUALIFICATIONS
November 2023: National Scientific Qualification achieved for the position of Full Professor in the Physiology disciplinary sector.
November 2020: National Scientific Qualification achieved for the position of Associate Professor in the Physiology disciplinary sector.
● EDUCATION HISTORY
2014: Doctoral Degree in Biomedical Science, curriculum Neurophysiology, University of Bologna. Doctoral thesis in: “Pharmacological rescue of dendritic pathology in the Ts65Dn mouse model of Down syndrome”. Supervisor: Prof. Renata Bartesaghi.
2010: Master of Science at the University of Bologna in Medical Biotechnology with thesis in: Definition of steroid reference intervals in adult and young population through Liquid Chromatography combined to Tandem Mass Spectrometry (LC-MS/MS). Grades 110 cum laude/110.
2007: Bachelor of Science at the University of Bologna in Biotechnology with thesis in: Analysis of the expression of phospholipase Cβ1 in myelodysplastic syndromes (MDS) after treatment with azacytidine. Grades 107/110.
2004: Scientific High-school Certificate achieved with 100/100 scores.
● SCIENTIFIC TRAINING
February 2020-october 2022. Junior Assistant Professor in Physiology, Department for Life Quality Studies, University of Bologna, Italy.
January 2014-january 2020: Postdoctoral Research Fellow, Department of Biomedical and Neuromotor Sciences, University of Bologna, Italy.
January 2011-december 2013: PhD Student in Biomedical Science, curriculum Neurophysiology, University of Bologna. Tutor: Prof.ssa Renata Bartesaghi.
● TEACHING EXPERIENCE
2021-today: Course of Physiology of Nutrition for the Second Cycle Degree in Human Nutrition, Well-being and Health, University of Bologna, Italy.
2021-today: Course of Physiology of Nutrition for the Second Cycle Degree in Sciences and Techniques of Sports Activities, University of Bologna, Italy.
2020-today: Course of Skin and Skin Annexes Physiology for the Second Cycle Degree in Advanced Cosmetic Sciences, University of Bologna, Italy.
Supervisor of the thesis in Second Cycle Degree in Human Nutrition, Well-being and Health, University of Bologna of Dr. Calendo Ciro entitled “Ruolo dei microRNA nel metabolismo glucidico e lipidico e analisi della modulazione della loro espressione in relazione alla dieta” (Academic year 2022/2023).
Supervisor of the thesis in Second Cycle Degree in Human Nutrition, Well-being and Health, University of Bologna of Dr. Andrea Filipozzi entitled “Bassa disponibilità energetica: eziologia e conseguenze di tale condizione sulle funzioni fisiologiche e sulla prestazione sportiva negli atleti” (Academic year 2022/2023).
Supervisor of the thesis in Second Cycle Degree in Human Nutrition, Well-being and Health, University of Bologna of Dr. Simone Marcatti entitled “Ruolo del microbiota intestinale nella salute mentale” (Academic year 2022/2023).
Supervisor of the thesis in Single Cycle Degree in Pharmacy, University of Bologna, of Dr. Giada Guerra entitled “Effects of adolescent treatment with the flavonoid 7,8-Dihydroxyflavone on the BDNF-TrkB system and hippocampus-dependent learning and memory in a mouse model of Down syndrome” (Academic year 2021/2022).
Supervisor of the thesis in Second Cycle Degree in Molecular and cellular Biology, University of Bologna, of Dr. Laura Angelozzi entitled “Adolescent pharmacotherapy with 7,8-dihydroxyflavone rescues dendritic pathology and improves hippocampus-dependent memory in the Ts65Dn mouse model of Down syndrome” (Academic year 2021/2022).
Co-supervisor of the thesis in First Cycle Degree in Exsercise and Sport Sciences, Rimini Campus, University of Bologna of Dr. Camilla Curzi entitled “Fisiologia del tessuto adiposo nelle strategie di dimagrimento in ambito motorio e nutrizionale” (Academic year 2020/2021).
Co-supervisor of the thesis in First Cycle Degree in Exsercise and Sport Sciences, Rimini Campus, University of Bologna of Dr. Luca Miserocchi entitled “Effetti fisiologici dello stile di vita sulla memoria” (Academic year 2020/2021).
Co-supervisor of the thesis in First Cycle Degree in Exsercise and Sport Sciences, Rimini Campus, University of Bologna of Dr. Leo Mosesoh entitled “Gli effetti della stanchezza mentale sulla prestazione calcistica” (Academic year 2019/2020).
Co-supervisor of the Doctoral Thesis in Biomedical Sciences, University of Bologna, of Dr. Marco Emili entitled “Treatment with β-2 adrenergic receptor agonists: a tool for improving brain developmental alterations in Down syndrome? (Academic year 2019/2020).
● RESEARCH ACTIVITY
Co-author of 31 articles in peer-reviewed international journals and the chapter entitled “Epigallocatechin-3-gallate: linking neurogenesis, hippocampus, and Down syndrome” in the book “The Neuroscience of Development,” published by Academic Press.
ORCID ID: 0000-0002-2226-7844
Number of citations (Scopus, May 2025): 868
H-index (Scopus, May 2025): 16
The research activity primarily focuses on identifying therapeutic approaches for restoring brain development in individuals with Down syndrome. Numerous pieces of evidence from mouse models of Down syndrome and individuals with this condition indicate that defects in neurogenesis and neuronal maturation significantly contribute to cognitive disability. These alterations are present from the early stages of brain development.
During my doctoral thesis, I conducted studies using the Ts65Dn mouse model of Down syndrome. These studies demonstrated, for the first time, that it is possible to restore major brain development defects through early pharmacological therapy with fluoxetine, administered either prenatally or in the early postnatal period. Following this groundbreaking discovery that brain development defects due to the trisomic condition are reversible with early treatment, my research has focused on identifying the underlying mechanisms of cerebral alterations.
I have explored the effectiveness of alternative therapeutic strategies beyond fluoxetine, utilizing techniques such as immunohistochemistry, morphology, electrophysiology, and behavioral analysis. The goal is to provide the clinical community with experimental evidence regarding the safest and most effective molecules for initiating clinical studies in individuals with Down syndrome.
Recently, alongside these studies, I have also dedicated research efforts to analyzing brain alterations in fetal tissue from subjects with Down syndrome and expanding the characterization of Down syndrome mouse models from both neuroanatomical and functional perspectives.
● NATIONAL AND INTERNATIONAL GRANTS
2024-today. EspeRare Foundation, Svizerland. Commissioned research. “Evaluating the effects of early versus late postnatal treatment with an antithrombotic drug on neurodevelopmental alterations and cognitive performance in a mouse model of Down syndrome”. Principal investigator.
2024-today. Fondazione del Monte, Italy. “Terapia precoce con astaxantina veicolata tramite nanoparticelle lipidiche: nuova strategia per il miglioramento delle funzioni cognitive nella sindrome di Down”. Principal investigator.
2023-today. Ministero dell’Università e della Ricerca, PRIN. “5G:SMILE (5G technology: bridging in vitro and in Silico Models to Investigate the interaction mechanisms at cellular LEvel)”. Co-investigator.
2022-today. HORIZON-HLTH-2021-ENVHLTH-02. “GOLIAT (5G expOsure, causaL effects, and rIsk perception through citizen engAgemenT)”. Co-investigator.
2021-2024. Jerome Lejeune Foundation, France. “Effect of adolescent treatment with the flavonoid 7,8-DHF on brain wiring, synaptic plasticity and cognitive performance in a model of Down syndrome”. Principal investigator.
2022-2023. Fondazione Carisbo, Italy. “Astaxantina: un potente antiossidante per prevenire lo sviluppo dell’Alzheimer nella sindrome di Down”. Co-investigator.
2021-2023. Fondazione Carisbo, Italy. “Terapia adolescenziale con beta2 agonisti approvati per uso pediatrico: nuova strategia per ripristinare i circuiti cerebrali nella sindrome di Down”. Co-investigator.
2019-2021. Fondazione del Monte, Italy. “Ruolo della regione CA2 dell’ippocampo nei difetti di memoria sociale correlati all’autismo”. Co-investigator.
2018-2020. Fondazione Mariani, Italy. “Preventive therapy for intellectual disability in Down syndrome with a flavonoid agonist of the TrkB receptor for BDNF”. Co-investigator
2018-2019. Jerome Lejeune Foundation, France. “Prenatal treatment with a BDNF mimetic: a potential strategy for improving brain development in the Ts65Dn mouse model of Down syndrome”. Co-investigator.
2015-2019. Fondazione Generali e Assicurazioni Generali, Italy. "New avenues for the rescue of intellectual disability in Down syndrome". Co-investigator.
2013-2015. Jerome Lejeune Foundation, France. “In the search of new therapies for the rescue of brain development in Down syndrome”. Co-investigator.
2012-2015. Fondazione Telethon, Italy. "Preventive therapy of mental retardation in Down syndrome by a novel gamma-secretase inhibitor: focus on APP-dependent mechanisms in neurodevelopment" (GGP12149)”. Co-investigator.
2011-2013. Jerome Lejeune Foundation, Italy. “Early pharmacotherapy to rescue brain development and cognitive performance in Down syndrome”. Co-investigator.
● FELLOWSHIPS AND AWARDS
Classified as top 0.1% World Expert in Down syndrome in Expertscape (https://expertscape.com/pro_hub/tweetup?1486612974529916933).
Second prize for the best EYPS Slam Communication in the European Young Physiologists’ Symposium (Bologna, September 2019).
“Young Investigator Travel Grant” for the participation to the 3rd International Congress of the Trisomy 21 Research Society (Barcelona, 2019).
"Carnot training fellowship" in the framework of a collaboration with Dr. Marie-Claude Potier from the Institut du Cervaeu et de la Moelle Epiniere (ICM Institute). Paris, France (March 1-March 31, 2018).
“Young Investigator Travel Grant” for the participation to the 2nd International Congress of the Trisomy 21 Research Society (Chicago, 2017).
Selected as one of the ten top finalists running for the national prize “Giovedì Scienza Sesta Edizione” (2017).
“ECNP Travel Award 2016” for the abstract entitled “Neurogenesis in the hippocampal dentate gyrus of a Down syndrome model can be restored by neonatal treatment with an agonist of the BDNF TrkB receptor”.
“Annette Karmiloff-Smith Dissertation Award” of the Trisomy 21 Research Society for the best PhD thesis in the field of Down syndrome (defended in 2014 and 2015).
“Junior Investigator Travel Grant” for the participation to the 1st International Congress of the Trisomy 21 Research Society (Paris, 2015).
● PATENT DEVELOPMENT
Filing in the United States of the patent no.: 10,945,989 B2. Title "Perinatal treatment with a flavonoid agonist of the TrkB receptor for BDNF rescues neurogenesis and behavior in the Ts65Dn mouse model of DS". Co-inventor with Prof. Renata Bartesaghi.
● INSTITUTIONAL ACTIVITIES
2023-today. Head of the Education and Training Committee of Trisomy 21 Research Society.
2022-today. Member of the Review Editorial Board of the section “Neurogenesis” of “Frontiers of Neuroscience”.
2019-today. Member of the “Down Syndrome and other Genetic Developmental Disorders Network” of the European College of Neuropsychopharmacology (ECNP).
2022-today. Member of the Joint Committee, Department for Life Quality Studies, University of Bologna, Italy.
2021-2024. Member of the Quality Assurance Management Commission of the Master's Degree Course in “Nutrizione Umana, Benessere e Salute”, Rimini Campus, University of Bologna, Italy.
2019-2023. Member of the Education and Training Committee of Trisomy 21 Research Society.
● AFFILIATION TO SCIENTIFIC SOCIETIES
Trisomy 21 Research Society (T21RS), European College of Neuropsychopharmacology (ECNP), Federation of European Neuroscience Associations (FENS), Società Italiana di Fisiologia (SIF).
● ORGANIZATION OF SCIENTIFIC EVENTS
Organizer of the “T21RS World Down Syndrome Day Webinar 2025”, April 3rd and May 5th, 2025.
Member of the Local Organizing Committee of the 5th International Conference of the Trisomy 21 Research Society that will be held in Rome, June 5-8, 2024.
Organizer of T21RS World Down Syndrome Day Webinar, April 4th, 2024.
Organizer of T21RS Webinar “Epigenetic aging in Down syndrome”, speaker: Dr. Maria Giulia Bacalini, January 31, 2024.
Moderator of the session “La ricerca di nuovi target terapeutici”, VII National Scientific Conference “Sindrome di Down: dalla ricerca alla terapia”, October 20-21, 2023.
Moderator of the session “Nuove ipotesi e prospettive terapeutiche”, VI National Scientific Conference “Sindrome di Down: dalla ricerca alla terapia”, October 21-22, 2022.
● PARTICIPATION TO NATIONAL AND INTERNATIONAL CONGRESSES
Invited Speaker
Stagni F. “Potential of early pharmacotherapies for the improvement of intellectual disability of Down syndrome: lesson from the Ts65Dn mouse model”. NICO Neurowebinar & Seminar. Neuroscience Institute Cavalieri Ottolenghi. Turin, Italy. March 24, 2023.
Stagni F. “The flavonoid 7,8-DHF improves postnatal neurogenesis in the subventricular zone of the Ts65Dn model of Down syndrome”. V Convegno Sindrome di Down: dalla diagnosi alla terapia. Virtual; 15-16 Ottobre 2021.
Stagni F. “The benefit of early therapy in Down syndrome: lesson from the Ts65Dn mouse model”.
International Session of IV Convegno Sindrome di Down: dalla diagnosi alla terapia. Virtual; 16-17 October 2020.
Stagni F. “New pharmacological approaches targeted to neurogenesis and dendritogenesis alterations in Down syndrome”. Symposium: Pharmacological rescue of circuit and dendritic alterations in intellectual disabilities. 33rd European College of Neuropsychopharmacology (ECNP) Congress. Virtual; 12-15 September 2020.
Stagni F. “Advance in pharmacotherapies for Down syndrome: lessons from mouse models”. Research seminars 2019-2020 of the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC). Santander, Spain; 5 December 2019.
Stagni F. “Alla ricerca di nuove terapie per migliorare lo sviluppo del cervello nella sindrome di Down”. III Convegno Sindrome di Down: dalla diagnosi alla terapia. Napoli, Italy; 18-19 October 2019.
Stagni F. “A BDNF mimetic can rescue trisomy-linked neurodevelopmental alterations”. European Young Physiologists‘Symposium; Joint meeting of the Federation of European Physiological Societies
and the Italian Physiological Society. Bologna, Italy; 10-13 September 2019.
Stagni F. “Perinatal therapy with a BDNF mimetic: a winning card for the rescue of intellectual disability in Down syndrome? World Congress of Neurology and Brain Disorders. Parigi; 15-16 November 2019.
Stagni F. “Prenatal pharmacotherapy with a BDNF mimetic elicits a widespread rescue of neurogenesis in a mouse model of Down syndrome. Society for Neuroscience DS Social "Down syndrome: from Neurobiology to Treatment" organized by Professor William Mobley. San Diego (CA), USA; 5 November 2018.
Stagni F. “A che punto sono arrivati i trial clinici?”. II Convegno Sindrome di Down: dalla diagnosi
alla terapia. Napoli, Italy; 19-20 October 2018.
Stagni F. “Potential of early pharmacotherapies for prevention of intellectual disability in Down syndrome”. 2nd PCS International Conference of Neuroscience. Prague, Czech Republic; 28-29 April 2018.
Stagni F. “In the search of safe therapy for improving brain development in Down syndrome”. Institut du Cervaeu et de la Moelle Epiniere (ICM Institute), Parigi, France; 23 April 2018.
Stagni F. “Una sostanza naturale, il 7,8-diidrossiflavone, ripristina le funzioni di memoria in un modello di sindrome di Down”. Convegno sindrome di Down. Salute e qualità di vita per le persone con la sindrome di down. Padova, Italy; 17 Marzo 2018.
Stagni F. “In the search of safe therapies for Down syndrome”. 5th International Conference on Brain Disorders and Therapeutics. Madrid, Spain; 29-30 November 2017.
Stagni F, Giacomini A, Guidi S, Emili M, Bartesaghi R. ”Inhibition of APP gamma-secretase: a promising tool for improving brain development in Down syndrome and APP-linked brain disorders?” 9th International Conference and Exhibition Pharmacovigilance & Drug Safety. Munich, Germany; 17-18 July 2017.Stagni F, Giacomini A, Guidi S, Emili M, Uguagliati B, Salvalai ME, Grilli M, Rimondini R, Bartesaghi R. “Therapy for intellectual disability in Down syndrome with a flavonoid agonist of the TrkB receptor for BDNF”. 2nd International Conference of the Trisomy 21 Research Society, Chicago, USA; 7-11 June 2017.
Stagni F. “Cellule staminali neurali: potenziare la memoria”. Unistem Day 2014. Bologna, Italy; 14 Marzo 2014.
Stagni F, Bianchi P, Calzà L, Ciani E, Guidi S, Ragazzi E, Trazzi S, Bartesaghi R. “Pharmacological rescue of hippocampal progenitor cell proliferation and differentiation in the Ts65Dn mouse model of Down syndrome”. Opportunity and challenges in the pharmacological modulation of adult neural stem cells. Novara, Italy; 14-15 December 2012.
Abstract
Angelozzi L, Emili M, Santonocito D, Zini F, Russo C, Puglia C, Stagni F, Guidi S. “La somministrazione neonatale di astaxantina tramite nanoparticelle ha un effetto pro-proliferativo nel modello murino Ts65Dn”. Book of Abstracts, 8th National Scientific Conference, “Sindrome di Down: dalla Ricerca alla Terapia”, Ottobre 18-19, 2024.
Ravaioli F, Emili M, Russo C, Angelozzi L, Dall’Olio D, Pellegrini C, De Fanti S, Morandi L, Gentilini D, Calzari L, Cavagnola R, Guidi S, Bartesaghi R, Stagni F, Bacalini M. “Analisi dell’espressione genica in ippocampi di topi Ts65Dn sottoposti a trattamento adolescenziale con il BDNF-mimetico 7,8 diidrossiflavone”. Book of Abstracts, 8th National Scientific Conference, “Sindrome di Down: dalla Ricerca alla Terapia”, Ottobre 18-19, 2024.
Angelozzi L, Emili M, Santonocito D, Zini F, Russo C, Stagni F, Puglia C, Guidi S. “Neonatal treatment with astaxanthin-loaded stealth lipid nanoparticles fosters hippocampal neurogenesis in a mouse model of Down syndrome”. Book of Abstracts, BraYn Conference-7th Brainstorming Research Assembly for Young Neuroscientists. Verona, Italia, 9-11 Ottobre 2024.
Angelozzi L, Emili M, Santonocito D, Zini F, Russo C, Bergamini C, Stagni F, Puglia C, Guidi S. “Effects of neonatal treatment with astaxanthin-loaded stealth lipid nanoparticles on hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome” Book of Abstracts, 5th International Conference of the Trisomy 21 Research Society”, Roma, Giugno 5-8 2024.
Ravaioli F, Emili M, Russo C, Angelozzi L, Dall’Olio D, Pellegrini C, De Fanti S, Morandi L, Gentilini D, Calzari L, Cavagnola R, Guidi S, Bartesaghi R, Stagni F, Bacalini MG. Effects of 7,8-dihydroxyflavone treatment on DNA methylation profiles of adolescent Ts65Dn mice hippocampus. 5th International Conference of the Trisomy 21 Research Society”, Roma, Giugno 5-8 2024.
Emili M, Alvente S, Bastianini S, Berteotti C, Guidi S, Lo Martire V, Matteoli G, Miglioranza E, Silvani A, Stagni F, Zoccoli G, Bartesaghi R. Sleep fragmentation causes neuronal loss in the hippocampal region of a mouse model of Down syndrome. Book of Abstracts, 5th International Conference of the Trisomy 21 Research Society”, Roma, Giugno 5-8 2024.
Ravaioli F, Emili M, Russo C, Angelozzi A, Dall’Olio D, Pellegrini P, De Fanti S, Morandi L, Gentilini D, Calzari L, Cavagnola R, Guidi S, Bartesaghi R, Bacalini MG, Stagni F. “Il trattamento adolescenziale con il BDNF mimetico 7,8-diidrossiflavone influenza la metilazione del DNA nell’ippocampo del modello Ts65Dn di sindrome di Down”. Book of Abstracts, 7th National Scientific Conference, “Sindrome di Down: dalla Ricerca alla Terapia”, Ottobre 20-21, 2023.
Angelozzi L, Emili M, Guidi S, Russo C, Aicardi G, Bartesaghi R, Stagni F. “Early pharmacotherapies for the rescue of intellectual disability in Down syndrome”. Book of abstracts, 16th Annual Meeting of Young Researchers in Physiology (The Italian Society of Physiology), Bertinoro, Italy, June 21-23, 2023.
Russo C, Emili M, Guidi S, Angelozzi L, Aicardi G, Bartesaghi R, Stagni F. “Adolescence represents an important window of opportunity for the rescue of dendritic pathology with a BDNF mimetic in a mouse model of Down syndrome”. Book of Abstracts, More than Neurons - Changing the paradigm for novel therapeutic avenues (3rd edition), Turin, Italy, December 15-17, 2022.
Russo C, Emili M, Guidi S, Angelozzi L, Aicardi G, Bartesaghi R, Stagni F. “Trattamento adolescenziale con il BDNF mimetico 7,8-diidrossiflavone: una strategia utile per migliorare lo sviluppo della fascia dentata ippocampica nel modello Ts65Dn di sindrome di Down”. Book of abstracts, 6th National Scientific Conference, “Sindrome di Down: dalla Ricerca alla Terapia”, Ottobre 21-22, 2022.
Russo C, Emili M, Guidi S, Angelozzi L, Aicardi G, Bartesaghi R, Stagni F. “Administration of the BDNF mimetic 7,8-Dihydroxyflavone during adolescence rescues neuron maturation and improves hippocampus-dependent memory in the Ts65Dn mouse model of Down syndrome”. Book of abstracts, 72nd SIF National Congress (The Italian Society of Physiology). Bari, Italy, September 14-16, 2022.
Russo C, Emili M, Guidi S, Aicardi G, Bartesaghi R, Stagni F. “Adolescent treatment with the BDNF mimetic 7,8-Dihydroxyflavone rescues dendritic pathology and improves hippocampus-dependent memory in the Ts65Dn mouse model of Down syndrome”. Book of Abstracts, 4th International Conference of the T21 Research Society, June 9-12, 2022, Long Beach, California (USA.
Stagni F, Emili M, Guidi S, Aicardi G, Bartesaghi R. “Early treatment with nutraceuticals and drugs for the rescue of intellectual disability in Down syndrome”. 2nd International Conference on Neuroprotection by Drugs, Nutraceuticals, and Physical Activity, Virtual; December 9-10, 2021.
Emili M, Uguagliati B, Stagni F, Guidi S, Bartesaghi R. “The Ts65Dn mouse model of DS shows dendritic alterations in neocortical pyramidal neurons at early life stages”. 71st SIF National Congress, The Italian Society of Physiology. Milan (Online); September 7-9, 2021.
Giacomini A, Stagni F, Emili M, Uguagliati B, Bartesaghi R, Guidi S. “Absence of sex differences in learning and memory, as assessed with the Morris Water Maze test, in adolescent Ts65dn mice”. 3rd International Congress of the Trisomy 21 Research Society Barcelona. Spain; June 6-9, 2019.
Guidi S, Stagni F, Giacomini A, Emili M, Uguagliati B, Bonasoni P, Bartesaghi R. “Impaired development of thalamic nuclei involved in executive function in fetuses with Down syndrome”. 3rd International Congress of the Trisomy 21 Research Society Barcelona. Spain; June 6-9, 2019.
Emili M, Stagni F, Giacomini A, Uguagliati B, Bartesaghi R, Guidi S. “Prenatal pharmacotherapy with a BDNF mimetic restores neurogenesis in the Ts65dn mouse model”. 3rd International Congress of the Trisomy 21 Research Society Barcelona. Spain; June 6-9, 2019.
Uguagliati B, Stagni F, Giacomini A, Emili M, Bartesaghi R, Guidi S. “Early impairment of dendritic development in the Ts65dn mouse model of Down syndrome”. 3rd International Congress of the Trisomy 21 Research Society Barcelona. Spain; June 6-9, 2019.
Stagni F, Giacomini A, Uguagliati B, Emili M, Salvalai ME, Grilli M, Bartesaghi R, Guidi S. “New hits identified in a drug screening campaign as promising tools for the rescue of neurodevelopmental alterations in Down syndrome”. 3rd International Congress of the Trisomy 21 Research Society Barcelona. Spain; June 6-9, 2019.
Uguagliati B, Stagni F, Emili M, Giacomini A, Guidi S, Bartesaghi R. “Prenatal therapy with a BDNF mimetic elicits a widespread rescue of neurogenesis in a mouse model of Down syndrome”. ECNP Workshop for Junior Scientists in Europe. Nice, France; March 7-10, 2019.
Uguagliati B, Salvalai ME, Stagni F, Guidi S, Giacomini A, Emili M, Xia E, Grilli M, Bartesaghi R "Exploiting different drugs for restoring proliferation ability and/or phenotype acquisition of trisomic neural progenitor cells”. More than Neurons Congress. Turin, Italy; December 1-3, 2018.
Guidi S, Stagni F, Giacomini A, Emili M, Uguagliati B, Bonasoni MP, Bartesaghi R (2018). “Developmental alterations in the subiculum of fetuses with Down syndrome and in the Ts65Dn model of Down syndrome”. Neuroscience 2018. San Diego, CA, USA; November 3-7, 2018.
Potier MC, Albac C, Stagni F, Emili M, Grilli M, Bartesaghi R, (2018). “Neurogenesis deficits in Down syndrome: testing recovery with GABAα5 negative allosteric modulator, β2 adrenergic agonist and
IGF-1 in Ts65Dn mice”. Neuroscience 2018. San Diego, CA, USA; November 3-7, 2018.
Stagni F, Salvalai ME, Uguagliati B, Emili M, Guidi S, Giacomini A, Bortolotto V, Grilli M, Bartesaghi R (2018). “Spinogenesis impairment can be rescued by neonatal treatment with a beta 2-adrenergic
agonist in a mouse model of Down syndrome”. Neuroscience 2018. San Diego, CA, USA; November 3-7, 2018.
Albac C, Stagni F, Bartesaghi R, Potier MC (2018). “Neurogenesis deficits in Down syndrome: testing
recovery with GABAα5 negative allosteric modulator, β2 adrenergic agonist and IGF-1 in Ts65Dn mice”. 31st ECNP Congress. Barcelona, Spain; October 6-9, 2018.
Stagni F, Salvalai M.E, Guidi S, Giacomini A, Emili M, Uguagliati B, Grilli M., Bartesaghi R (2018).
“Treatment with kaempferol: a possible tool to restore neurogenesis in Down syndrome?”. 31st ECNP
Congress. Barcelona, Spain; October 6-9, 2018.
Uguagliati B, Salvalai ME, Stagni F, Guidi S, Giacomini A, Emili M, Bortolotto V, Grilli M, Bartesaghi R (2018). “Treatment with a beta 2-adrenergic agonist restores dendritic pathology in a mouse model
of Down syndrome” BRAYN: Brainstorming research Assembly for Young Neuroscientists. Genova, Italy; June 29-30, 2018.
Stagni F, Giacomini A, Emili M, Uguagliati B, Guidi S, Bartesaghi R (2018). “Early treatment with a BDNF mimetic: a suitable therapy for Down syndrome?” FENS-SfN Summer School: Neural stem cells,
brain organoids and brain repair. Bertinoro, Italy; June 2-9, 2018.
Giacomini A, Stagni F, Emili M, Guidi S, Salvalai ME, Vidal-Sanchez V, Grilli M, Martinez-Cué C, Bartesaghi R (2018) “Selective inhibitors of gsk-3β: a suitable therapy for Down syndrome?” ECNP Workshop for Junior Scientists in Europe. Nice, France; March 15-18, 2018.
Emili M, Stagni F, Giacomini A, Uguagliati B, Bartesaghi R, Guidi S. (2018) “Favoring neurogenesis in DS: the power of natural compounds”, Convegno SINS Dottorandi in Neuroscience. Napoli, Italy; February 23, 2018.
Guidi S, Emili M, Giacomini A, Stagni F, Bartesaghi R (2017) “Neuroanatomical alterations in the temporal cortex of human fetuses with Down syndrome”. 2nd International Conference of T21RS. Chicago, IL, USA; June 8-11, 2017.
Giacomini A, Roncacè V, Burattini C, Stagni F, Guidi S, Emili M, Aicardi G, Bartesaghi R (2017) “Neuroanatomical and functional alterations in the perirhinal cortex of the Ts65Dn model of Down syndrome”. 2nd International Conference of T21RS. Chicago, IL, USA; June 8-11, 2017.
Giacomini A, Stagni F, Emili M, Guidi S, Grilli M, Martinez-Cuè C, Bartesaghi R. (2017) “Treatment with tideglusib does not improve cognitive performance in the Ts65Dn mouse model of DS”. 2nd International Conference of T21RS. Chicago, IL, USA; June 8-11, 2017.
Stagni F, Raspanti R, Giacomini A, Guidi S, Emili M, Ciani E, Giuliani A, Bighinati A, Calzà L, Magistretti J, Bartesaghi R. (2017) “Short- and long-term effects of neonatal pharmacotherapy with a selective γ-secretase inhibitor on hippocampal development in the Ts65Dn mouse model of Down syndrome” XIX Convention Telethon. Riva Del Garda, Italy; March 13-15, 2017.
Giacomini A, Stagni F, Emili M, Guidi S, Ciani E, Vidal Sanchez V, Martinez-Cué C, Bartesaghi R. ”Tideglusib does not restore neurogenesis and cognitive performance in the Ts65Dn mouse model of DS”. More Than Neurons Congress. Turin, Italy; December 1-3, 2016.
Stagni F, Giacomini A, Emili M, Guidi S, Ciani E, Bortolotto V, Salvalai ME, Grilli M, Bartesaghi R. ”Treatment with 7,8-DHF positively impacts on brain developmental alterations in a mouse model of Down syndrome”. More Than Neurons Congress. Turin, Italy; December 1-3, 2016.
Stagni F, Emili M, Giacomini A, Guidi S, Ciani E, Bartesaghi R. “Neurogenesis in the hippocampal dentate gyrus of Down syndrome model can be restored by a neonatal treatment with an agonist of the BDNF TrkB receptor”. 29th ECNP Congress of Applied and Translational Neuroscience. Wien, Austria; September 17-20, 2016.
Raspanti A, Salvioli L, Stagni F, Guidi S, Giacomini A, Basi GS, Bartesaghi R, Magistretti J. (2015) “Hippocampal synaptic connectivity in a mouse model of Down syndrome: effects of a novel γ-secretase inhibitor” 66th SIF National Congress Genova, Italy; September 16-18, 2015.
Stagni F, Giacomini A, Trazzi S, Emili M, Guidi S, Ciani E, Bartesaghi R. “Neonatal treatment with epigallocatechin-3-gallate reinstates hippocampal development in the Ts65Dn mouse model of Down syndrome”. 1st International Conference of the Trisomy 21 Research Society. Paris, France; June 4-7, 2015.
Giacomini A, Stagni F, Trazzi S, Guidi S, Emili M, Basi G, Brigham B, Raspanti A, Magistretti J, Ciani E, Bartesaghi R. (2015) “A novel gamma-secretase inhibitor restores neurodevelopmental alterations in the Ts65Dn mouse model of Down syndrome” XVIII Convention Telethon. Riva Del Garda, Italy; March 9-11, 2015.
Stagni F, Trazzi S, Giacomini A, Guidi S, Emili M, Ciani E & Bartesaghi R. (2014) “Treatment with Epigallocathechin gallate rescues neurogenesis and neuron maturation in the Ts65Dn mouse model for Down syndrome” XXII National Congress of the Italian Society of Psychophysiology. “Dalle Neuroscienze di base alla Neuroriabilitazione”. Firenze, Italy; November 27-29, 2014.
Raspanti A, Alessi C, Stagni F, Giacomini A, Guidi S, Basi G, Brigham B, Ciani E, Bartesaghi R. “ Effects of early pharmacological treatment with a γ-secretase inhibitor on spontaneous and miniature synaptic activity in CA3 pyramidal cells in a mouse model of Down syndrome”. 65th SIF National Congress. Anacapri, Italy; September 28-30, 2014.
Stagni F, Giacomini A, Ciani E, Guidi S, Bartesaghi R. “Therapy with fluoxetine prevents early signs of AD-like pathology in the Ts65Dn mouse model of Down syndrome”. New Targets in Neurodegenerative Diseases: Emphasis on advances in Alzheimer’s Disease research. Braga, Portugal; August 31-September 5, 2014.
Giacomini A, Stagni F, Trazzi S, Guidi S, Ragazzi E, Basi G, Brigham B, Ciani E, Bartesaghi R. “A novel gamma-secretase inhibitor restores neurodevelomental alterations in Down syndrome” 9th FENS Forum of Neuroscience. Milano, Italy; July 5-9, 2014.
Bartesaghi R, Stagni F, Giacomini A, Ciani E, Guidi S. “Early signs of AD-like pathology are prevented by early pharmacotherapy with fluoxetine in the Ts65Dn mouse model for Down syndrome”. Hinxton Meeting, Cambridge, UK; March 27-29, 2014.
Stagni F, Guidi S, Bianchi P, Ciani E, Ragazzi E, Trazzi S, Mangano C, Calzà L, Bartesaghi R. Dendritic pathology and connectivity can be rescued by pharmacotherapy with fluoxetine in the Ts65Dn mouse model of Down syndrome. 6th Meeting Young Researchers in Physiology. Sestri Levante, Italy; May 30-June 1, 2012.
Guidi S, Stagni F, Ragazzi E, Bianchi P, Bartesaghi R. Pharmacotherapy with fluoxetine rescues dendritic hypotrophy in the Ts65Dn mouse model for DS. 8th World Congress of IBRO. Firenze, Italy; July 14-18, 2011.
